Project

ETOP 2-11 (BELIEF) An open-label phase II trial of erlotinib and bevacizumab in pa-tients with advanced non-small cell lung cancer and activating EGFR mutations

Automatically Closed · 2012 until 2022

Früh Martin, Siano Marco, Jörger Markus